|
Adenocarcinoma of lung (disorder)
|
0.030 |
Biomarker
|
disease |
BEFREE |
<b>Conclusion:</b> The mRNA signature of AURKA, CDC20 and TPX2 were potential biomarkers for predicting poor prognosis of smoking related lung adenocarcinoma.
|
30588191 |
2018 |
|
Adenocarcinoma of lung (disorder)
|
0.030 |
AlteredExpression
|
disease |
BEFREE |
Moreover, the concurrent overexpression of WDR62 and TPX2, a WDR62-interacting protein that is also overexpressed in LAC, induced centrosome amplification in the lung cells.
|
28277612 |
2017 |
|
Adenocarcinoma of lung (disorder)
|
0.030 |
AlteredExpression
|
disease |
BEFREE |
In the cancer genome atlas (TCGA) lung adenocarcinoma cohort, high expression levels of AURKA and TPX2 were associated with specifically improved overall survival upon taxane-based radiochemotherapy, but not in case of non-taxane-based radiochemotherapy, chemo- or radiotherapy only.
|
28869599 |
2018 |
|
Adenocarcinoma of pancreas
|
0.010 |
Biomarker
|
disease |
BEFREE |
The targeting protein for Xklp2 (TPX2) has recently gained attention as a putative oncogene possibly amplified in several human malignancies, including pancreatic adenocarcinoma.
|
19861455 |
2009 |
|
Adenoma of large intestine
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
Chromosome 20q DNA copy number status correlated significantly with TPX2 and AURKA protein levels in a series of colorectal adenomas and carcinomas.
|
22207630 |
2012 |
|
Adult Hepatocellular Carcinoma
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
Subgroup analysis revealed that increased TPX2 expression was related to worse prognosis of gastric cancer and hepatocellular cancer, while irrelevant to esophageal squamous cell cancer at 5-year survival rate.
|
30412141 |
2018 |
|
Adult Liver Carcinoma
|
0.010 |
Biomarker
|
disease |
BEFREE |
This study aimed to investigate the role and mechanism of action of targeting protein for Xklp2 (TPX2) in liver cancer, we compared TPX messenger RNA (mRNA) expression in liver cancer tissue samples and adjacent normal liver tissue samples as well as in human liver cancer cell lines and nonmalignant cell line by quantitative reverse transcription polymerase chain reaction (qRT-PCR).
|
30548299 |
2018 |
|
Adult Lymphoma
|
0.010 |
GeneticVariation
|
disease |
BEFREE |
Assays of a series of additional lymphoma-associated NF-kappaB-2 truncation suggested that the C-terminal truncation associated with these proteins was also associated with a loss of the IkappaB-like activities of p100 NF-kappaB-2, for at least some NF-kappaB target promoters.
|
10713675 |
2000 |
|
Adult Non-Hodgkin Lymphoma
|
0.010 |
Biomarker
|
disease |
BEFREE |
A novel Aurora kinase A inhibitor MK-8745 predicts TPX2 as a therapeutic biomarker in non-Hodgkin lymphoma cell lines.
|
21879811 |
2012 |
|
Adult T-Cell Lymphoma/Leukemia
|
0.010 |
Biomarker
|
disease |
BEFREE |
Together, these results suggest that the cytoplasmic interplay of Tax and p100 may play an important role in the initiation and maintenance of HTLV-1 latency observed in adult T-cell leukemia.
|
8289813 |
1994 |
|
Alzheimer's Disease
|
0.020 |
Biomarker
|
disease |
BEFREE |
Protective effects and mechanism of TPX2 on neurocyte apoptosis of rats in Alzheimer's disease model.
|
28352333 |
2017 |
|
Alzheimer's Disease
|
0.020 |
Biomarker
|
disease |
BEFREE |
Increased P100 amplitude and latency may reflect reduced amygdala volume and disruptions in the visual system, while decreased N170 and increased VPP amplitudes may reflect impaired perceptual processing, mitigated by a greater involvement of prefrontal areas for task performance in AD.
|
31401490 |
2019 |
|
Anxiety
|
0.010 |
Biomarker
|
disease |
BEFREE |
Anxiety-like behaviour was assessed at P100.
|
30415249 |
2018 |
|
Anxiety Disorders
|
0.010 |
Biomarker
|
group |
BEFREE |
Anxiety-like behaviour was assessed at P100.
|
30415249 |
2018 |
|
Astrocytoma
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
TPX2 protein expression was detected in the nucleus of astrocytoma tissues by immunohistochemistry and immunofluorescence staining.
|
20599806 |
2010 |
|
Bipolar Disorder
|
0.010 |
Biomarker
|
disease |
BEFREE |
Individuals with BD in a euthymic state have reduced P50 sensory gating and reduced P100 amplitudes compared with healthy controls.
|
29981961 |
2018 |
|
Bladder Neoplasm
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
Among them, four hub genes (CCNB1, KIF4A, TPX2, and TRIP13) were eventually identified by using five different methods (survival analysis, one-way analysis of variance, the Spearman correlation analysis, receiver operating characteristic curve, and expression value comparison), which were significantly correlated with the prognosis of BC.
|
30927274 |
2019 |
|
bone destruction
|
0.010 |
Biomarker
|
disease |
BEFREE |
These findings suggest that upregulation of TRAF3 or NF-kappaB p100 expression or inhibition of NF-kappaB p100 degradation in OCPs could limit bone destruction and inflammation-induced bone loss in common bone diseases.
|
19770515 |
2009 |
|
Bone Diseases
|
0.010 |
Biomarker
|
group |
BEFREE |
These findings suggest that upregulation of TRAF3 or NF-kappaB p100 expression or inhibition of NF-kappaB p100 degradation in OCPs could limit bone destruction and inflammation-induced bone loss in common bone diseases.
|
19770515 |
2009 |
|
Breast Carcinoma
|
0.040 |
Biomarker
|
disease |
BEFREE |
In short, all the results suggested that miR-491 functioned as a tumor suppressor by targeting TPX2 in BC and the miR-491 restoration may be an effective therapy for the BC treatment in the future.
|
31799669 |
2019 |
|
Breast Carcinoma
|
0.040 |
GeneticVariation
|
disease |
BEFREE |
Following on these observations, we further assessed the link between the AURKA-HMMR-TPX2-TUBG1 functional module and risk of breast cancer in BRCA1 or BRCA2 mutation carriers.
|
25830658 |
2015 |
|
Breast Carcinoma
|
0.040 |
AlteredExpression
|
disease |
BEFREE |
However, although p100 is highly expressed in a number of breast cancer cell lines, MHC Class I antigen expression was observed on all the cell lines we analysed and could be further induced by stimulation with the cytokines IFN-gamma or TNF-alpha.
|
9681829 |
1998 |
|
Breast Carcinoma
|
0.040 |
Biomarker
|
disease |
BEFREE |
Opposing roles of Nfkb2 gene products p100 and p52 in the regulation of breast cancer stem cells.
|
28190248 |
2017 |
|
Cancer of Digestive System
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
TPX2 expression might be associated with TNM stage and pathological grade in digestive system cancer.
|
29551902 |
2018 |
|
Carcinogenesis
|
0.070 |
Biomarker
|
phenotype |
BEFREE |
CDK5-mediated phosphorylation and stabilization of TPX2 promotes hepatocellular tumorigenesis.
|
31272499 |
2019 |